摘要
目的：观察参麦注射液治疗老年急性脑梗死的疗效和安全性。方法：急性脑梗死８０例，分为２组。参麦组 ４２例，子参麦注射液 ６０ ｍＬ，抗栓酶组３８例子蝮蛇抗栓酶０．５ Ｕ，均溶于０．９％氯化钠注射液 ２５０ ｍＬ， ｉｖ ｄｒｉｐ，ｑｄ × １０ ｄ。结果：参麦组有效率 ７８％，抗栓酶组 ７１％，差异无显著意义（ Ｐ＞０． ０５）。但参麦组开始用药时间＜ １ｄ， １—３ ｄ和＞４－７ ｄ组间比较差异有显著意义（Ｐ＜ ０． ０５）。红细胞膜腺苷三磷酸酶活力上升，２组比较，差异有非常显著意义（Ｐ＜０．０１）。２组均无严重不良反应。结论：参麦注射液治疗老年人急性脑梗死疗效显著、安全。
AIM: To observe clinical effects and safety of Shenmai Zhusheye in the treatment of acute cerebral infarction. METHODS: The patients(n = 80) suffering from acute cerebral infaration were divided into two groups. Forty-two patients in Shenmai group (age 72 a +- s 10 a) were injected with Shenmai Zhusheye 60 mL in 0. 9 % sodium Chloride 250 mL, iv, drip,qd for 10 d as a course, while thirty-eight patients in control group (age 74 a +- 10 a) were injected with Fushekangshuanmei Zhusheye in the same way. RESULTS: The total effective rates was 78 % for Shenmai group, and 77 % for control group, respectively. There was no significant difference between the two groups (P >0. 05). Shenmai group was significant difference in patients with onset< 1 d than 1-l3 d and 4-7 d (P < 0. 05). The Shenmai group showed noticeable effects in raising activity of adeno- sine triphosphatase in erythrocyte membranes (P < 0. 01). Both groups had not severe adverse reactions. CONCLUSION: Shenmai Zhusheye is Safe and effective in treating acute cerebral infarction.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2000年第2期96-98,共3页
Chinese Journal of New Drugs and Clinical Remedies
关键词
急性脑梗死
中医药疗法
参麦注射液
老年人
Panax ginseng
Ophiopogon japonicus
Fushekangshuanmei
aged
cerebral infarction
erythrocyte membrane
adenosine triphosphatase
